MMV (Medicines for Malaria Venture) and Zydus Cadila (Indian pharmaceutical company headquartered at Ahmedabad in Gujarat state of western India) have announced a collaboration to develop the investigational antimalarial compound MMV253.
“Zydus Cadila and Medicines for Malaria Venture (MMV) announced a collaboration to develop the investigational anti-malarial compound, MMV674253. Zydus will lead the development of the novel compound and MMV will provide support, including scientific expertise and access to tools in malaria drug development and delivery,” Zydus Cadila’s listed group firm Cadila Healthcare said in a BSE filing.
“Malaria is a major global health risk and its menace has only worsened with the problem of artemisinin-resistance. By collaborating with Medicines for Malaria Venture in this initiative, we hope to usher in a step change in the treatment of this deadly disease,” said Pankaj R. Patel, Chairman and Managing Director, Zydus. “This molecule has a novel mechanism of action, rapidly kills parasites across all intra-erythrocytic stages and has a long half-life, which means it might even lead to a single-dose cure for P. falciparum malaria.”
For the full story please visit : http://www.mmv.org/newsroom/press-releases/mmv-and-zydus-join-forces-develop-new-antimalarial
[source : http://www.mmv.org/newsroom/press-releases/mmv-and-zydus-join-forces-develop-new-antimalarial, http://www.dnaindia.com/money/report-zydus-cadila-goes-for-collaboration-for-anti-malaria-drug-2260089]